Clinical Trials Directory

Trials / Terminated

TerminatedNCT00120380

Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)

Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Hannover Medical School · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to test whether the addition of inhaled iloprost is safe and effective in patients with idiopathic pulmonary arterial hypertension who are already being treated with the endothelin receptor antagonist bosentan.

Conditions

Interventions

TypeNameDescription
DRUGAerosolized iloprost
DRUGPlacebo

Timeline

Start date
2004-09-01
Primary completion
2006-05-01
Completion
2006-05-01
First posted
2005-07-18
Last updated
2012-08-21

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00120380. Inclusion in this directory is not an endorsement.

Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH) (NCT00120380) · Clinical Trials Directory